Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative)

v3.19.2
Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)
 1 Months Ended
Jul. 15, 2019
Aug. 14, 2019
Proceeds from issuance of preferred stock $ 13,800,000  
Line of credit facility, description   The Company has drawn $3.4 million of the $4.0 million of available funds under its Revolving Line; $250,000 of the Line of Credit has been used to secure the issuance of a LOC by SVB. As such, the amount available under the line is $3.75 million. The funds drawn were used in conjunction with the acquisition of the BioPharma Business of CGI.
Withdrawn of available funds   $ 3,400,000
Line of credit   4,000,000
Secured debt   250,000
Available line of credit   3,750,000
Line of credit remaining amount   $ 325,000
CGI, Gentris, LLC [Member]    
Business acquisition assets acquired and liabilities assumed 23,500,000  
Business acquisition assets acquired and liabilities assumed, adjustment 1,980,000  
Notes payable $ 7,692,300  
Interest rate 6.00%  
Ampersand 2018 Limited Partnership [Member] | Asset Purchase Agreement [Member] | Preferred Stock [Member]    
Stock issued for acquisition, value $ 27,000,000  
Ampersand 2018 Limited Partnership [Member] | Asset Purchase Agreement [Member] | Preferred Stock [Member] | Tranche One [Member]    
Stock issued for acquisition, value 14,000,000  
Ampersand 2018 Limited Partnership [Member] | Asset Purchase Agreement [Member] | Preferred Stock [Member] | Tranche Two [Member]    
Stock issued for acquisition, value $ 13,000,000